ES2709357T3 - Métodos de predicción del desenlace de un cáncer en un paciente analizando la expresión génica - Google Patents

Métodos de predicción del desenlace de un cáncer en un paciente analizando la expresión génica Download PDF

Info

Publication number: ES2709357T3
Authority: ES; Spain
Prior art keywords: genes; group; combination; particular embodiment; ren
Prior art date: 2011-01-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES16193596T

Other languages

English (en)

Spanish (es)

Inventor

Jérôme Galon

Franck Pages

Bernard Mlecnik

Herve Fridman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Assistance Publique Hopitaux de Paris APHP

Institut National de la Sante et de la Recherche Medicale INSERM

Universite Paris Descartes

Original Assignee

Assistance Publique Hopitaux de Paris APHP

Institut National de la Sante et de la Recherche Medicale INSERM

Universite Paris Descartes

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-11

Filing date

2012-01-11

Publication date

2019-04-16

2012-01-11 Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Descartes filed Critical Assistance Publique Hopitaux de Paris APHP

2019-04-16 Application granted granted Critical

2019-04-16 Publication of ES2709357T3 publication Critical patent/ES2709357T3/es

Status Active legal-status Critical Current

2032-01-11 Anticipated expiration legal-status Critical

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 129
201000011510 cancer Diseases 0.000 title claims abstract description 94
238000000034 method Methods 0.000 title claims abstract description 57
230000014509 gene expression Effects 0.000 title claims abstract description 55
108090000623 proteins and genes Proteins 0.000 claims abstract description 789
102100022790 BTB/POZ domain-containing protein KCTD11 Human genes 0.000 claims abstract description 282
101000974815 Homo sapiens BTB/POZ domain-containing protein KCTD11 Proteins 0.000 claims abstract description 282
101000579218 Homo sapiens Renin Proteins 0.000 claims abstract description 282
101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims abstract description 265
102100033461 Interleukin-17A Human genes 0.000 claims abstract description 265
101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 claims abstract description 252
102100030304 Platelet factor 4 Human genes 0.000 claims abstract description 252
102100021186 Granulysin Human genes 0.000 claims abstract description 251
101001040751 Homo sapiens Granulysin Proteins 0.000 claims abstract description 251
101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims abstract description 241
102100037850 Interferon gamma Human genes 0.000 claims abstract description 241
102100032367 C-C motif chemokine 5 Human genes 0.000 claims abstract description 198
101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims abstract description 198
101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims abstract description 188
102100022341 Integrin alpha-E Human genes 0.000 claims abstract description 188
101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims abstract description 158
102100040120 Prominin-1 Human genes 0.000 claims abstract description 158
102100038393 Granzyme H Human genes 0.000 claims abstract description 156
101001033000 Homo sapiens Granzyme H Proteins 0.000 claims abstract description 156
102100026214 Indian hedgehog protein Human genes 0.000 claims abstract description 144
101710139099 Indian hedgehog protein Proteins 0.000 claims abstract description 144
101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims abstract description 126
102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims abstract description 126
101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims abstract description 109
102000017578 LAG3 Human genes 0.000 claims abstract description 109
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims abstract description 100
102100039037 Vascular endothelial growth factor A Human genes 0.000 claims abstract description 100
102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims abstract description 98
101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims abstract description 98
102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims abstract description 89
101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims abstract description 89
239000000523 sample Substances 0.000 claims description 45
239000012472 biological sample Substances 0.000 claims 1
210000001519 tissue Anatomy 0.000 description 15
150000007523 nucleic acids Chemical class 0.000 description 13
230000003321 amplification Effects 0.000 description 12
238000003199 nucleic acid amplification method Methods 0.000 description 12
108020004707 nucleic acids Proteins 0.000 description 12
102000039446 nucleic acids Human genes 0.000 description 12
238000011282 treatment Methods 0.000 description 11
238000009396 hybridization Methods 0.000 description 9
206010009944 Colon cancer Diseases 0.000 description 6
208000001333 Colorectal Neoplasms Diseases 0.000 description 6
238000004393 prognosis Methods 0.000 description 6
230000036962 time dependent Effects 0.000 description 6
101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 5
210000001165 lymph node Anatomy 0.000 description 5
238000002493 microarray Methods 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000000463 material Substances 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
238000003757 reverse transcription PCR Methods 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
238000007475 c-index Methods 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
238000012552 review Methods 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
208000005024 Castleman disease Diseases 0.000 description 2
238000000018 DNA microarray Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
101100341507 Mus musculus Itgae gene Proteins 0.000 description 2
108020004711 Nucleic Acid Probes Proteins 0.000 description 2
238000011529 RT qPCR Methods 0.000 description 2
201000010208 Seminoma Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000002790 cross-validation Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
201000003115 germ cell cancer Diseases 0.000 description 2
239000011521 glass Substances 0.000 description 2
201000011066 hemangioma Diseases 0.000 description 2
238000007834 ligase chain reaction Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
238000010606 normalization Methods 0.000 description 2
239000002853 nucleic acid probe Substances 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000002271 resection Methods 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
101150034533 ATIC gene Proteins 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
208000007860 Anus Neoplasms Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
102100026031 Beta-glucuronidase Human genes 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
208000010126 Chondromatosis Diseases 0.000 description 1
208000019591 Chondromyxoid fibroma Diseases 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
208000006402 Ductal Carcinoma Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
208000004057 Focal Nodular Hyperplasia Diseases 0.000 description 1
201000004066 Ganglioglioma Diseases 0.000 description 1
208000000527 Germinoma Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
206010019629 Hepatic adenoma Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 1
101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 1
101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
208000005125 Invasive Hydatidiform Mole Diseases 0.000 description 1
208000035663 Invasive mole Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
208000001715 Osteoblastoma Diseases 0.000 description 1
208000000035 Osteochondroma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
108020001027 Ribosomal DNA Proteins 0.000 description 1
208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
208000000728 Thymus Neoplasms Diseases 0.000 description 1
201000000170 Thyroid lymphoma Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
201000011165 anus cancer Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
208000026900 bile duct neoplasm Diseases 0.000 description 1
208000020790 biliary tract neoplasm Diseases 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
201000011143 bone giant cell tumor Diseases 0.000 description 1
201000005389 breast carcinoma in situ Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
201000007273 ductal carcinoma in situ Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
238000001861 endoscopic biopsy Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
208000032099 esthesioneuroblastoma Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
201000000079 gynecomastia Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
201000006866 hypopharynx cancer Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
201000011059 lobular neoplasia Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
201000005163 papillary serous adenocarcinoma Diseases 0.000 description 1
208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
210000003695 paranasal sinus Anatomy 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
201000002511 pituitary cancer Diseases 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
201000009463 pleomorphic rhabdomyosarcoma Diseases 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
208000000649 small cell carcinoma Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
208000010576 undifferentiated carcinoma Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1

Landscapes

Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

ES16193596T 2011-01-11 2012-01-11 Métodos de predicción del desenlace de un cáncer en un paciente analizando la expresión génica Active ES2709357T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11305024		2011-01-11
US201161434514P	2011-01-20	2011-01-20

Publications (1)

Publication Number	Publication Date
ES2709357T3 true ES2709357T3 (es)	2019-04-16

Family

ID=66087590

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES16193596T Active ES2709357T3 (es)	2011-01-11	2012-01-11	Métodos de predicción del desenlace de un cáncer en un paciente analizando la expresión génica

Country Status (3)

Country	Link
ES (1)	ES2709357T3 (tr)
PT (1)	PT3141617T (tr)
TR (1)	TR201901231T4 (tr)

2012
- 2012-01-11 PT PT16193596T patent/PT3141617T/pt unknown
- 2012-01-11 TR TR2019/01231T patent/TR201901231T4/tr unknown
- 2012-01-11 ES ES16193596T patent/ES2709357T3/es active Active

Also Published As

Publication number	Publication date
PT3141617T (pt)	2019-02-08
TR201901231T4 (tr)	2019-02-21

Publication	Publication Date	Title
ES2609249T3 (es)	2017-04-19	Métodos de predicción del desenlace de un cáncer en un paciente analizando la expresión génica
CN103834729B (zh)	2016-09-14	肺癌的多基因预后试验
ES2754434T3 (es)	2020-04-17	Métodos de pronóstico de cáncer de próstata
CN105102636B (zh)	2019-08-13	用于检测和测定前列腺癌预后的组合物和方法
KR20120065959A (ko)	2012-06-21	위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
ES2608322T3 (es)	2017-04-07	Procedimiento para predecir la respuesta a la quimioterapia en un paciente que padece o está en riesgo de desarrollar cáncer de mama recurrente
JP6240258B2 (ja)	2017-11-29	ｍｉＲＮＡの発現を分析することによって大腸癌の転帰を予測するための方法
US20220093251A1 (en)	2022-03-24	Novel biomarkers and diagnostic profiles for prostate cancer
ES2828923T3 (es)	2021-05-28	Prueba de metilación de ADN para detectar cáncer de próstata
KR102194215B1 (ko)	2020-12-22	위암 진단용 바이오마커 및 이의 용도
Mengual et al.	2014	Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers
US20190284642A1 (en)	2019-09-19	Biomarkers for the prognosis and diagnosis of cancer
KR20210144353A (ko)	2021-11-30	단일세포 전사체 분석에 기반한 대장암의 예후 예측 방법
ES2709357T3 (es)	2019-04-16	Métodos de predicción del desenlace de un cáncer en un paciente analizando la expresión génica
ES2544882T3 (es)	2015-09-04	Determinación del riesgo de metástasis distante en pacientes con cáncer de pulmón de células no pequeñas en estadio I-IIIA, tratados quirúrgicamente
Kang et al.	2012	FAM70B as a novel prognostic marker for cancer progression and cancer-specific death in muscle-invasive bladder cancer
US20210147944A1 (en)	2021-05-20	Methods for monitoring and treating prostate cancer
JPWO2015115544A1 (ja)	2017-03-23	大腸がんの転移又は再発リスクの評価方法
ES2343996B1 (es)	2011-06-20	Metodo para la subclasificacion de tumores.
JP6051166B6 (ja)	2017-04-05	遺伝子の発現を分析することによって患者における癌の転帰を予測するための方法
Issa et al.	2018	Hsa-microRNA-101-3p expression in human urinary bladder cancer: Correlation with tumor pathology
Homøe et al.	2018	MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study.
JPWO2015115545A1 (ja)	2017-03-23	乳がんの転移又は再発リスクの評価方法
CA2815263A1 (en)	2012-04-26	Use of specific genes or their encoded proteins for a prognosis method of classified lung cancer